CRYOPORT, INC. Interest Expense Nonoperating
CRYOPORT, INC. (CYRX) reported Interest Expense Nonoperating of $518.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Interest Expense
us-gaap:InterestExpenseNonoperating · last filed 2026-08-06
- CRYOPORT, INC. interest expense nonoperating for the quarter ending 2026-06-30 was $518.00K, a 16.18% decline year-over-year.
- CRYOPORT, INC. interest expense nonoperating for the quarter ending 2026-03-31 was $432.00K, a 25.90% decline year-over-year.
- CRYOPORT, INC. interest expense nonoperating for the quarter ending 2025-12-31 was $634.00K, a 9.50% increase year-over-year.
- CRYOPORT, INC. interest expense nonoperating for the quarter ending 2025-09-30 was $526.00K, a 40.36% decline year-over-year.
- CRYOPORT, INC. interest expense nonoperating for fiscal 2025 was $2.36M, a 40.63% decline from fiscal 2024.
- CRYOPORT, INC. interest expense nonoperating for fiscal 2024 was $3.98M, a 28.73% decline from fiscal 2023.
- CRYOPORT, INC. interest expense nonoperating for fiscal 2023 was $5.58M, a 9.15% decline from fiscal 2022.
- CRYOPORT, INC. interest expense nonoperating for fiscal 2022 was $6.14M.
| Period end | Interest Expense Nonoperating 3 month | Interest Expense Nonoperating 3 month as first filed | Interest Expense Nonoperating 6 month | Interest Expense Nonoperating 6 month as first filed | Interest Expense Nonoperating 9 month | Interest Expense Nonoperating 9 month as first filed | Interest Expense Nonoperating 12 month | Interest Expense Nonoperating 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $518.00K 10-Q · filed 2026-08-06 | $950.00K 10-Q · filed 2026-08-06 | $1.58M derived: sum of 3 quarters · filed 2026-08-06 | $2.11M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2026-03-31 | $432.00K 10-Q · filed 2026-05-05 | $1.07M derived: sum of 2 quarters · filed 2026-05-05 | $1.59M derived: sum of 3 quarters · filed 2026-05-05 | $2.21M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-12-31 | $634.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $1.16M derived: sum of 2 quarters · filed 2026-03-05 | $1.78M derived: sum of 3 quarters · filed 2026-08-06 | $2.36M 10-K · filed 2026-03-05 | ||||
| 2025-09-30 | $526.00K 10-Q · filed 2025-11-06 | $1.14M derived: sum of 2 quarters · filed 2026-08-06 | $1.73M 10-Q · filed 2025-11-06 | $2.31M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-06-30 | $618.00K 10-Q · filed 2026-08-06 | $1.20M 10-Q · filed 2026-08-06 | $1.78M derived: sum of 3 quarters · filed 2026-08-06 | $2.66M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-03-31 | $583.00K 10-Q · filed 2026-05-05 | $1.16M derived: sum of 2 quarters · filed 2026-05-05 | $2.04M derived: sum of 3 quarters · filed 2026-05-05 | $3.29M derived: sum of 4 quarters · filed 2026-05-05 | ||||
| 2024-12-31 | $579.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $1.46M derived: sum of 2 quarters · filed 2026-03-05 | $2.70M derived: sum of 3 quarters · filed 2026-03-05 | $3.98M 10-K · filed 2026-03-05 | $4.11M 10-K · filed 2025-03-07 | |||
| 2024-09-30 | $882.00K 10-Q · filed 2025-11-06 | $889.00K 10-Q · filed 2024-11-07 | $2.12M derived: sum of 2 quarters · filed 2025-11-06 | $3.40M 10-Q · filed 2025-11-06 | $3.47M 10-Q · filed 2024-11-07 | $4.78M derived: sum of 4 quarters · filed 2026-03-05 | ||
| 2024-06-30 | $1.24M 10-Q · filed 2025-08-12 | $1.25M 10-Q · filed 2024-08-08 | $2.52M 10-Q · filed 2025-08-12 | $2.58M 10-Q · filed 2024-08-08 | $3.90M derived: sum of 3 quarters · filed 2026-03-05 | $5.26M derived: sum of 4 quarters · filed 2026-03-05 | ||
| 2024-03-31 | $1.27M 10-Q · filed 2025-05-08 | $2.66M derived: sum of 2 quarters · filed 2026-03-05 | $4.01M derived: sum of 3 quarters · filed 2026-03-05 | $5.35M derived: sum of 4 quarters · filed 2026-03-05 | ||||
| 2023-12-31 | $1.38M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $2.74M derived: sum of 2 quarters · filed 2026-03-05 | $4.07M derived: sum of 3 quarters · filed 2026-03-05 | $5.58M 10-K · filed 2026-03-05 | $5.50M 10-K · filed 2025-03-07 | |||
| 2023-09-30 | $1.36M 10-Q · filed 2024-11-07 | $2.69M derived: sum of 2 quarters · filed 2024-11-07 | $4.20M 10-Q · filed 2024-11-07 | |||||
| 2023-06-30 | $1.33M 10-Q · filed 2024-08-08 | $2.84M 10-Q · filed 2024-08-08 | ||||||
| 2022-12-31 | $6.14M 10-K · filed 2025-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |